Business
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
SARASOTA, Fla., Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\" or the \"Company\"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, today announced the Company received notice from The Nasdaq Capital Market, LLC (\"Nasdaq\"), dated November 22, 2023, informing INVO that it has regained compliance with the minimum stockholders' equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor for a period of one year from the date of the notification.\n\n \n \n \n \n \n \n\n \nNasdaq had previously notified INVO on November 23, 2022 that INVO was not in compliance with the minimum stockholders' equity rule because it failed to maintain stockholders' equity of at least $2,500,000. In order to regain compliance with the rule, the Company was required to demonstrate stockholder's equity of at least $2,500,000.\nOn November 20, 2023, the Company entered into a share exchange agreement with Cytovia Therapeutics Holdings, Inc. (\"Cytovia\") for Cytovia's acquisition of 1,200,000 shares of the Company's newly designated Series B Preferred Stock in exchange for 163,637 shares of common stock of NAYA Biosciences Inc. (\"NAYA\") held by Cytovia valued at $6,000,000. On November 20, 2023, the Company and Cytovia closed on the exchange of shares. Prior to the share exchange, Cytovia owned $50,000,000 in NAYA shares which it received as partial consideration for the acquisition by NAYA of two NK Engager bi-specific antibodies targeting, respectively, GPC3 for the treatment of Hepatocellular Carcinoma and CD38 for the treatment of Multiple Myeloma.\nAs a result of the exchange and based on the significant reduction in net loss demonstrated in INVO's Form 10-Q for the quarter ended September 30, 2023, the ongoing and further expected reduction in certain operating costs, including the end of research and development expenses related to securing FDA clearance for the INVOcell label update, and profits from the operations of our previously-acquired clinic, Wisconsin Fertility Institute, the Company's stockholders' equity was sufficient to maintain its Nasdaq listing.\nAs previously...